Department of Urology, University of Illinois at Chicago, 820 South Wood Street MC 955, Chicago, IL, 60612, USA.
Division of Hematology and Oncology, University of Illinois at Chicago, 840 South Wood Street MC 713, Chicago, IL, 60612, USA.
BMC Cancer. 2017 Sep 25;17(1):659. doi: 10.1186/s12885-017-3640-7.
Current evidence on risk of prostate cancer following a diagnosis of male breast cancer is limited and guidance for screening in this potentially higher-risk population remainsunclear. Our objective was to quantify prostate cancer risk in men diagnosed with breast cancer.
We identified men diagnosed with first primary breast cancer between 1988 and 2012 using the Surveillance, Epidemiology and End Results Program registry databases. Men were followed for occurrence of a second primary prostate cancer and secondary outcomes of cancer-specific and overall survival. Stratified analyses were performed by age, breast cancer stage, race, and breast cancer hormone receptor status. Excess risk per 10,000 person-years and standardized incidence ratios (SIR) with 95% confidence intervals (95% CI) were calculated. We used multivaraible Cox proportional hazard models to estimate hazard ratios (HR) and 95% CI for characteristics associated with secondary prostate cancer and survival.
From a cohort of 5753 men with breast cancer with median follow up of 4.3 years, we identified 250 cases of second primary prostate cancer. Overall, the incidence of second primary prostate cancer was modestly greater than expected (SIR = 1.12, 95% CI 0.93-1.33), although not statistically significant. Stratified analyses demonstrated associations for men ages 65-74 at the time of breast cancer diagnosis (SIR = 1.34, 95%CI 1.01-1.73), hormone receptor-positive breast cancer (SIR = 1.23, 95%CI 1.11-1.39) or AJCC stage I breast cancer (SIR = 1.36, 95%CI 1.04-1.75) and second primary prostate cancer diagnosis.
The incidence of prostate cancer in men with history of breast cancer is similar to the general population. Men with favorable characteristics of their breast cancer were more likely to develop prostate cancer, possibly due to a lower competing risk of breast cancer mortality.
目前,男性乳腺癌患者罹患前列腺癌的风险证据有限,对于这一潜在高风险人群的筛查指导尚不明确。本研究旨在量化男性乳腺癌患者罹患前列腺癌的风险。
我们利用监测、流行病学和最终结果计划登记数据库,确定了 1988 年至 2012 年间被诊断为原发性乳腺癌的男性。对这些男性进行了随访,以观察其是否发生第二原发前列腺癌,并观察了癌症特异性生存和总体生存的次要结局。我们按照年龄、乳腺癌分期、种族和乳腺癌激素受体状态进行了分层分析。计算了每 10000 人年的超额风险和标准化发病比(SIR)及其 95%置信区间(95%CI)。我们使用多变量 Cox 比例风险模型来估计与第二原发前列腺癌和生存相关的特征的风险比(HR)和 95%CI。
在 5753 名中位随访时间为 4.3 年的乳腺癌男性患者队列中,我们发现了 250 例第二原发前列腺癌病例。总体而言,第二原发前列腺癌的发病率略高于预期(SIR=1.12,95%CI 0.93-1.33),但无统计学意义。分层分析显示,在诊断乳腺癌时年龄为 65-74 岁(SIR=1.34,95%CI 1.01-1.73)、激素受体阳性乳腺癌(SIR=1.23,95%CI 1.11-1.39)或 AJCC Ⅰ期乳腺癌(SIR=1.36,95%CI 1.04-1.75)的男性,其第二原发前列腺癌的发病率更高。
有乳腺癌病史的男性前列腺癌的发病率与普通人群相似。具有乳腺癌有利特征的男性更有可能罹患前列腺癌,这可能是由于乳腺癌死亡率的竞争风险降低。